文献速递淋巴瘤

原发纵隔B细胞淋巴瘤一线免疫化疗后的结局:一项LYSA研究

Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.
PubMed 文献 · Blood Adv · 2021-01-01

这项多中心回顾性研究纳入法国和比利时25个中心的313例原发纵隔B细胞淋巴瘤患者,比较R-ACVBP与R-CHOP14/21方案的真实世界结局。仅5.4%患者接受纵隔放疗。基线TMTV≥360 cm3与更差的无进展生存相关。

要点

  • R-ACVBP与R-CHOP14的3年PFS均达89.4%,优于R-CHOP21的74.7%
  • R-ACVBP的发热性中性粒细胞减少和黏膜炎发生率显著高于R-CHOP方案
  • 基线TMTV≥360 cm3是PFS的不良预后因素(HR 2.18)

核心结论

  • 接受剂量密集免疫化疗且未放疗的原发纵隔B细胞淋巴瘤患者结局良好。
  • R-ACVBP的急性毒性高于R-CHOP14。
  • 基线TMTV的预后重要性得到证实。

研究设计与样本

  • 法国和比利时25个中心的大型多中心回顾性研究。
  • 共纳入313例原发纵隔B细胞淋巴瘤患者。
  • 患者接受R-ACVBP(n=180)、R-CHOP14(n=76)或R-CHOP21(n=57),巩固策略因时间和机构而异,主要依据PET指导。

主要发现

  • 基线TMTV≥360 cm3与较低的无进展生存相关(HR 2.18;95%CI 1.05-4.53)。

关键数值与推荐

  • 基线TMTV≥360 cm3与较低的无进展生存相关(HR 2.18;95%CI 1.05-4.53)。

临床怎么用

  • 对于原发纵隔B细胞淋巴瘤,剂量密集免疫化疗(R-ACVBP或R-CHOP14)可带来优异的无进展生存。
  • 选择R-ACVBP时需注意其较高的急性毒性(发热性中性粒细胞减少和黏膜炎)。
  • 基线TMTV≥360 cm3提示预后较差,可用于风险分层。

局限性

  • 回顾性研究设计。
  • 巩固策略因时间和机构而异,存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma typically affecting young female patients. The first-line standard of care remains debated. We performed a large multicenter retrospective study in 25 centers in France and Belgium to describe PMBL patient outcomes after first-line treatment in real-life settings. A total of 313 patients were enrolled and received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) (n = 180) or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) delivered every 14 days (R-CHOP14, n = 76) or 21 days (R-CHOP21, n = 57) and consolidation strategies in modalities that varied according to time and institution, mainly guided by positron emission tomography. Consolidation autologous stem cell transplantation was performed for 46 (25.6%), 24 (31.6%), and 1 (1.8%) patient in the R-ACVBP, R-CHOP14, and R-CHOP21 groups, respectively (P < .001); only 17 (5.4%) patients received mediastinal radiotherapy. The end-of-treatment complete metabolic response rates were 86.3%, 86.8%, and 76.6% (P = .23) in the R-ACVBP, R-CHOP14, and R-CHOP21 groups. The median follow-up was 44 months, and the R-ACVBP, R-CHOP14, and R-CHOP21 three-year progression-free survival probabilities were 89.4% (95% confidence interval [CI], 84.8-94.2), 89.4% (95% CI, 82.7-96.6), and 74.7% (95% CI, 64-87.1) (P = .018). A baseline total metabolic tumor volume (TMTV) ≥360 cm3 was associated with a lower progression-free survival (hazard ratio, 2.18; 95% CI, 1.05-4.53). Excess febrile neutropenia (24.4% vs 5.3% vs 5.3%; P < .001) and mucositis (22.8% vs 3.9% vs 1.8%; P < .001) were observed with R-ACVBP compared with the R-CHOP regimens. Patients with PMBL treated with dose-dense immunochemotherapy without radiotherapy have excellent outcomes. R-ACVBP acute toxicity was higher than that of R-CHOP14. Our data confirmed the prognostic importance of baseline TMTV.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Camus V, Rossi C, Sesques P, et al. Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Adv. 2021. PMID: 34461634. doi:10.1182/bloodadvances.2021004778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。